$1.10 Million in Sales Expected for Xeris Pharmaceuticals Inc (NASDAQ:XERS) This Quarter
Equities analysts expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will announce sales of $1.10 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Xeris Pharmaceuticals’ earnings, with estimates ranging from $890,000.00 to $1.30 million. Xeris Pharmaceuticals reported sales of $800,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 37.5%. The business is expected to announce its next earnings results on Wednesday, March 4th.
On average, analysts expect that Xeris Pharmaceuticals will report full year sales of $1.83 million for the current financial year, with estimates ranging from $1.46 million to $2.20 million. For the next year, analysts anticipate that the company will post sales of $22.69 million, with estimates ranging from $22.17 million to $23.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last posted its earnings results on Thursday, November 7th. The company reported ($1.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million.
Shares of XERS stock traded down $0.06 during trading hours on Monday, reaching $6.13. The company had a trading volume of 59,424 shares, compared to its average volume of 319,361. Xeris Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $17.62. The company has a debt-to-equity ratio of 1.33, a current ratio of 5.96 and a quick ratio of 5.96. The business has a fifty day simple moving average of $7.61 and a 200-day simple moving average of $9.50. The company has a market cap of $167.13 million, a price-to-earnings ratio of -1.23 and a beta of -0.48.
In other Xeris Pharmaceuticals news, insider Paul R. Edick purchased 17,935 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $153,344.25. Following the completion of the acquisition, the insider now owns 172,935 shares of the company’s stock, valued at approximately $1,478,594.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Steven Prestrelski sold 10,000 shares of Xeris Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $5.50, for a total value of $55,000.00. Following the sale, the insider now owns 421,824 shares in the company, valued at $2,320,032. The disclosure for this sale can be found here. Company insiders own 7.43% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Bank of Montreal Can bought a new stake in shares of Xeris Pharmaceuticals in the second quarter valued at $26,000. Tower Research Capital LLC TRC acquired a new position in shares of Xeris Pharmaceuticals in the second quarter worth about $42,000. Marshall Wace North America L.P. acquired a new position in shares of Xeris Pharmaceuticals in the first quarter worth about $71,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Xeris Pharmaceuticals in the third quarter worth about $100,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Xeris Pharmaceuticals in the second quarter worth about $118,000. Institutional investors and hedge funds own 66.37% of the company’s stock.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Story: What is a stock split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.